Olmesartán/Amlodipino/Hidroclorotiazida Alter (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, amlodipine, and hydrochlorothiazide, the active ingredients in Olmesartán/Amlodipino/Hidroclorotiazida Alter, are a combination antihypertensive presented as an oral tablet for systemic use. The product is indicated for the management of high blood pressure in adult patients.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through strict adherence to Good Distribution Practice and provides reliable logistics to global markets. Our network supports timely delivery and regulatory support for importation.

Olmesartan/amlodipine/hydrochlorothiazide is a combination antihypertensive used to treat conditions related to elevated blood pressure.

- Essential hypertension: provides combined blockade of the renin‑angiotensin system, calcium‑channel mediated vasodilation, and diuretic action to achieve target blood pressure. - Hypertension in patients requiring multiple drug classes: simplifies therapy by delivering three antihypertensive mechanisms in a single tablet. - Hypertension with fluid retention: the thiazide component adds diuretic effect to reduce volume overload while the other agents lower vascular resistance.

Adverse reactions reported with the combination may vary in frequency and severity.

Common Side Effects: - Dizziness: light‑headed sensation, especially after dose initiation. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Flushing: transient warmth and reddening of the skin. - Fatigue: general feeling of tiredness. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function. - Electrolyte disturbances: significant changes in potassium or sodium levels. - Angioedema: rapid swelling of face, lips, or throat. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, consider patient‑specific factors and monitor relevant parameters.

- Blood pressure monitoring: ensure adequate control and avoid excessive lowering. - Renal function assessment: check serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: monitor potassium and sodium levels due to thiazide component. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; generally contraindicated. - Hypersensitivity: discontinue if patient exhibits rash, itching, or severe allergic reaction. - Store at room temperature: keep in original container, protect from moisture and light.

Drug‑drug interactions may alter efficacy or increase risk of adverse events.

Major Interactions (Avoid): - Concomitant use of aliskiren in patients with diabetes or renal impairment: risk of severe hypotension and renal dysfunction. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase amlodipine plasma concentrations, leading to toxicity. - Lithium therapy: thiazide component can raise lithium levels, precipitating toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Potassium‑sparing diuretics or supplements: increase risk of hyperkalemia when combined with olmesartan. - ACE inhibitors or other ARBs: additive effect on blood pressure and potential for renal impairment.